Daré Bioscience CEO Sabrina Martucci Johnson Named to Forbes 50 Over 50: Innovation List

San Diego, Calif. – Daré Bioscience, Inc. (NASDAQ: DARE) announced on August 18, 2026, that its President and CEO, Sabrina Martucci Johnson, has been named to the Forbes 2026 “50 Over 50: Innovation” list. This recognition places her among distinguished women innovators and entrepreneurs achieving significant career milestones later in life.

The Forbes list acknowledges women who have made substantial professional contributions and impact after the age of 50. Johnson's inclusion underscores the growing importance of women's health as a category for healthcare innovation. Daré Bioscience has dedicated over a decade to addressing unmet needs in women's health through scientific solutions.

Johnson founded Daré Bioscience in 2015 with a mission to identify, develop, and bring to market differentiated healthcare solutions for women's health. The company's current portfolio spans contraception, sexual health, menopause, vaginal health, fertility, and infectious diseases, encompassing both commercial products and pipeline development.

"Being recognized by Forbes is deeply meaningful, but what excites me most is what this recognition represents," said Sabrina Martucci Johnson. "For too long, enormous unmet needs in women’s health were accepted as simply the status quo. We built Daré Bioscience because we believed those gaps represented both an obligation to women and an opportunity for innovation."

The company is transitioning from a predominantly clinical-stage biotechnology firm to a multi-product women's health company. Key initiatives driving this evolution include the development of DARE to PLAY™ Sildenafil Cream, the commercial launch of Flora Sync LF5™, the investigational hormone-free contraceptive Ovaprene®, and the DARE-HPV program targeting HPV infections.